Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance

Long Gu, Sarah Waliany, Susan E. Kane

Division of Tumor Cell Biology, Beckman Research Institute of City of Hope, Duarte, California, United States of America

Abstract

Background: Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu). Up to 70% of Her2-positive breast cancers demonstrate a response to Herceptin-based therapies, but resistance almost inevitably arises within a year of the initial response. To help understand the mechanism of Herceptin resistance, we isolated clonal variants of Her2-positive BT474 human breast cancer cells (BT/Her6) that are highly resistant to Herceptin. These cell lines exhibit sustained PI3K/Akt signaling as an essential component of Herceptin-resistant proliferation. Several genes in the protein kinase A (PKA) signaling network have altered expression in BT/Her6 cells, including PPP1R1B, which encodes a 32 kDa protein known as Darpp-32 and its amino-terminal truncated variant, t-Darpp. The purpose of the current work was to determine the role of Darpp-32 and t-Darpp in Herceptin resistance.

Methodology and Results: We determined expression of Darpp-32 and t-Darpp in BT/Her6 cells selected for resistance to Herceptin. Subsequently, cDNAs encoding the two isoforms of Darpp-32 were transfected, separately and together, into Her2-positive SK-Br-3 breast cancer cells. Transfected cells were tested for resistance to Herceptin and Herceptin-mediated dephosphorylation of Akt. DNA binding activity by the cAMP response element binding protein (CREB) was also measured. We found that BT/Her6 cells overexpressed t-Darpp but not Darpp-32. Moreover, t-Darpp overexpression in SK-Br-3 cells was sufficient for conferring resistance to Herceptin and Herceptin-mediated dephosphorylation of Akt. Darpp-32 co-expression reversed t-Darpp’s effects on Herceptin resistance and Akt phosphorylation. t-Darpp overexpression led to increased CREB binding activity, which was also reversible by Darpp-32.

Conclusions: t-Darpp and Darpp-32 appear to have antagonistic effects on Herceptin resistance. We present a unified model by which these effects might be mediated via the PKA regulatory network.

Introduction

Her2, a member of the ErbB family of receptor tyrosine kinases, is overexpressed in about 25% of human breast cancers [1]. Herceptin (trastuzumab) is a humanized monoclonal antibody targeted to Her2 and approved for use against Her2-positive metastatic breast cancer [2]. Despite a fairly robust response rate to Herceptin-based therapies in these patients, resistance frequently arises within one year of an initial response [3–7]. The determinants of response or resistance to anti-cancer drugs are often complex. In the case of Herceptin, which works primarily by shutting down the PI3K/Akt signal transduction pathway, the key determinant of response appears to be the ability to modulate Akt phosphorylation. Failure to modulate phospho-Akt results in resistance [8–10].

Cells have several mechanisms by which to sustain Akt signaling in the face of Herceptin [9,11], including mutation of PI3K, the gene that codes for the p110α catalytic subunit of PI3K [12,13]; mutation or deletion of PTEN, whose product is a dual lipid/protein phosphatase responsible for down-modulating phosphatidylinositol 3,4,5 triphosphate that is the product of PI3K [13–15]; up-regulation or activation of receptor tyrosine kinases such as EGFR, Her3, IGF1R or MET to compensate for Her2 inhibition [16–20]; down-regulation of phosphatases that are responsible for dephosphorylating Akt as a negative feedback mechanism [21,22]; and up-regulation of phosphatase inhibitors that modulate the effect of those phosphatases and thus dampen the negative feedback [23]. There are also ways of bypassing phospho-Akt altogether, either by promoting signal transduction at a point downstream of Akt or by activating a parallel pathway(s) that can compensate for loss of PI3K/Akt signaling [24–26].

Using BT/Her6.1.0 cell lines selected in vitro for their resistance to 1 μM Herceptin [8], we have identified the protein kinase A (PKA) pathway as a possible central regulator of PI3K/Akt signaling and possible compensatory pathway for survival in the presence of Herceptin. In a separate report, we demonstrate that...
either stimulation of PKA with forskolin or down-regulation of the R1β regulatory subunit of PKA with siRNA was sufficient for conferring partial resistance to Herceptin-mediated growth arrest and Akt dephosphorylation (L. Gu and S.E. Kane, manuscript submitted). Additional PKA-related gene expression changes observed in BT/HerR1R clones include down-regulation of the PKIγ gene, whose product acts as an endogenous inhibitor of PKA [27]; down-regulation of the gene that codes for PTG (protein targeting to glycogen), a scaffold protein [28] that promotes the activity of PP-1, a downstream target for negative regulation by PKA and itself a negative regulator of Akt; and up-regulation of the PPP1R1B gene, which codes for Darpp-32, a substrate for and feedback inhibitor of PKA and also an inhibitor of PP-1 [29]. The PPP1R1B locus also codes for t-Darpp, a transcriptional variant and amino-truncated isoform of Darpp-32 whose function within the PKA pathway is not known, but which is overexpressed in many adenocarcinomas and has been associated with drug resistance in cell lines [30–33].

We now demonstrate that it was t-Darpp, and not Darrp-32, that was overexpressed in BT/HerR clones selected for Herceptin resistance and that transfection and overexpression of exogenous t-Darpp in Her2-positive SK-Br-3 cells was sufficient for conferring resistance to Herceptin and Herceptin-mediated dephosphorylation of Akt. Darrp-32 co-expression reversed t-Darpp’s effects on Herceptin resistance and Akt phosphorylation. Overexpression of t-Darpp also led to increased CREB binding activity, which was also reversible by Darrp-32. We present a model by which the PKA pathway and its regulatory components might impact cellular response to Herceptin.

Materials and Methods

Cell culture

The human breast cancer cell lines BT474 and SK-Br-3 were obtained from the American Type Culture Collection (Rockville, MD). BT474 cells were maintained in DMEM with 10% FBS and 1% penicillin/streptomycin in 5% CO₂. BT/HerR clones, previously derived from BT474 cells after a six-month selection in the continuous presence of Herceptin [8], were maintained in the same culture conditions as the BT474 cells. They were regularly tested in Herceptin-containing medium to verify their resistance. SK-Br-3 cells were maintained in McCoy’s Medium 5A with 10% FBS, 1% penicillin/streptomycin, and 1%L-glutamine in 5% CO₂.

Stable transfections

Darrp-32 and t-Darpp cDNAs were a kind gift from Wael El-Rifai. Darrp-32 was in the pcDNA3.1/Zeo vector. We subcloned the t-Darpp cDNA into the pcDNA3.0/Neo vector to remove a FLAG-tag present at the N-terminus of the received cDNA and restore its native sequence. Plasmid DNAs were transfected into SK-Br-3 cells or clones derived from SK-Br-3 cells by Lipofectamine 2000 according to manufacturer’s instructions. Briefly, double-stranded oligonucleotide containing a consensus CRE (cyclic AMP response element-binding protein) response element (CRE) was labeled with γ-32P ATP by end-labeling. DNA-protein binding reactions were performed by incubating 5 µg of nuclear protein with excess 32P-labeled CRE oligonucleotide in the buffer supplied with the assay kit. For competition binding, 1 pmol of an unlabeled CRE oligonucleotide was added. After incubation at room temperature for 20 min, binding reactions were resolved on a 4% native polyacrylamide gel. The gel was visualized by autoradiography.

Electrophoretic mobility shift assay

Nuclear extracts were prepared using CelLyte™ NuCLEAR™ Extraction Kit (Sigma, Saint Louis, MO). Electrophoretic mobility shift assay (EMSA) was done using a gel shift assay kit purchased from Promega (Madison, WI) according to manufacturer’s instructions. Briefly, double-stranded oligonucleotide containing a consensus CRE (cyclic AMP response element-binding protein) response element (CRE) was labeled with γ-32P ATP by end-labeling. DNA-protein binding reactions were performed by incubating 5 µg of nuclear protein with excess 32P-labeled CRE oligonucleotide in the buffer supplied with the assay kit. For competition binding, 1 pmol of an unlabeled CRE oligonucleotide was added. After incubation at room temperature for 20 min, binding reactions were resolved on a 4% native polyacrylamide gel. The gel was visualized by autoradiography.
then dried onto Whatman paper and radioactivity was visualized by autoradiography. The autoradiography images were digitized by a high-resolution scanner and the densities of individual bands were measured by ImageQuant™ 5.2 (GE Healthcare, Piscataway, NJ).

Results

Enhanced expression of t-Darpp in BT/HerR cell clones

We previously reported on the isolation and initial characterization of BT/HerR1.0 cell lines selected for their resistance to Herceptin at 1.0 μM concentration [8]. A salient feature of BT/HerR1.0 cells is their sustained phospho-Akt levels and Akt activity in the presence of Herceptin. As part of a separate study, gene expression profiling revealed that the PPP1R1B gene was up-regulated by 9- to 50-fold in two independent BT/HerR1.0 clones (raw microarray data are deposited in the Gene Expression Omnibus database, Accession No. GSE15043).

PPP1R1B encodes two transcription variants, Darpp-32 and t-Darpp [34], both of which hybridize to the same probe set on the Affymetrix GeneChip Human Genome U133 plus v2.0 array used for this analysis. To determine if one or both transcription variants encoded by the PPP1R1B gene were up-regulated in BT/HerR1.0 clones, we extracted RNAs from parent BT474 cells and two BT/HerR1.0 clones and measured Darpp-32 and t-Darpp mRNA levels in these cells. BT/HerR1.0 clones, which did not have up-regulated PPP1R1B in the microarray analysis (data not shown), were also analyzed in this experiment. Quantitative real-time RT-PCR revealed an increase in the t-Darpp mRNA levels in BT/HerR1.0 cells relative to parent BT474 cells, including a slight increase in the BT/HerR1.0 clones (Fig. 1A). In contrast, no significant up-regulation of Darpp-32 mRNA levels was observed in BT/HerR1.0 cells vs. BT474 cells. Consistent with the quantitative RT-PCR data, Western analysis confirmed that t-Darpp protein expression was up-regulated in all BT/HerR1.0 clones analyzed, whereas BT/HerR1.0 clones and their parent BT474 cells expressed similarly low levels of Darpp-32 protein (Fig. 1B). A longer exposure of the gel revealed detectable expression of the full-length Darpp-32 protein and perhaps a modest elevation of this protein in BT/HerR1.0 cells, relative to BT474 cells (Fig. 1B); but t-Darpp was clearly the predominant variant overexpressed in BT/HerR1.0 cells. This might suggest an overall activation of the PPP1R1B locus in these cells but preferential transcription from the downstream start site controlling t-Darpp mRNA expression. Since the protein data are not absolutely correlated with the mRNA data in Fig. 1A, there might also be an element of translational or post-translational control over Darpp-32/t-Darpp expression that is currently not understood. Further analysis of the PPP1R1B locus will be required to clarify the mechanisms regulating expression at the mRNA and protein levels.

Overexpression of t-Darpp confers Herceptin resistance

The purpose of the current study was to determine the phenotypic consequence of activating expression from the PPP1R1B locus. Since t-Darpp was the predominant form of the protein being expressed, we first asked if enhanced expression of t-Darpp is sufficient for conferring Herceptin resistance. We transfected a Her2-positive, Herceptin-sensitive human breast cancer cell line, SK-BR-3, with a cloned human t-Darpp cDNA as described in Materials and Methods. Independent clones stably transfected with t-Darpp were selected for their resistance to Herceptin. The SK.Br-3/t-Dp clones expressed both t-Darpp and Darpp-32, whereas SK.t-Dp clones expressed significant levels of t-Darpp protein (Fig. 2A). Herceptin inhibited the growth of the parent SK-BR-3 cells and SK.Neo clones but had no significant effect on the growth of SK.t-Dp clones (Fig. 2B). As a further test of the role of t-Darpp in Herceptin resistance, we measured phospho-Akt levels in SK.t-Dp and SK.Neo clones in the presence and absence of Herceptin. Herceptin caused an almost complete dephosphorylation of Akt in SK.Neo clones, whereas SK.t-Dp clones were able to maintain a significant level of intracellular phospho-Akt in the presence of Herceptin (Fig. 2C). Interestingly, we observed a reduction in phospho-Akt levels in some SK.t-Dp clones at 1 hour after the addition of Herceptin, followed by quick restoration of phospho-Akt by 2–3 hours in the sustained presence of Herceptin (Fig. 2C and data not shown), although this result was not reproducible in all clones. Although we do not know the reason for the transient loss of phospho-Akt in some SK.t-Dp clones, it suggests that Her2’s immediate response to Herceptin remains intact in at least some cell lines that overexpress t-Darpp.

Darpp-32 reverses Herceptin resistance conferred by t-Darpp

Although t-Darpp expression has been associated with malignant transformation and drug resistance, its exact mechanism of action is not known. The full-length Darpp-32, on the other hand, has been extensively studied in neural systems [29] but its possible function in malignancy is not known. We wanted to determine the effect of expressing high levels of Darpp-32 in the presence and absence of its truncated variant, t-Darpp. We transfected SK-BR-3 cells with the pcDNA3.1/Darpp-32 vector as described in Materials and Methods and tried to select clones stably expressing the full-length protein. Transfected clones grew poorly, however, and none with confirmed Darpp-32 expression survived long-term culturing. Out of a combined total of about 50 Zeocin-selected clones isolated from several independent transfection experiments, only 12 were able to grow as cultures and none of those expressed detectable levels of Darpp-32 protein.

These results suggested that Darpp-32 overexpression might be detrimental to cell proliferation and/or survival in SK-BR-3 cells. If true, then Darpp-32 and t-Darpp would appear to have opposite effects on cell growth. If Darpp-32 and t-Darpp do functionally antagonize each other, we reasoned that enhanced expression of Darpp-32 might reverse the Herceptin resistance phenotype conferred by t-Darpp overexpression. To test this hypothesis, we transfected Darpp-32 cDNA into the Herceptin-resistant SK.t-Dp.A clone and selected for zeocin-resistant clones. Out of 11 surviving clones tested, six expressed full-length Darpp-32 in addition to t-Darpp that was already expressed in these cells (Fig. 3A and data not shown). Thus, the presence of t-Darpp appeared to create a permissive environment for enhanced Darpp-32 expression that otherwise could not be achieved. We next tested these cells for their response to Herceptin. The SK.t-Dp/Dp32 clones that expressed both t-Darpp and Darpp-32 were sensitive to Herceptin-induced growth arrest (Fig. 3B). Moreover, Herceptin caused nearly a complete dephosphorylation of Akt in SK.t-Dp/Dp32 clones, similar to that observed in the parent SK-BR-3 cells (Fig. 3C) and SK.Neo clones (not shown).

t-Darpp and Darpp-32 have antagonistic effects on CRE binding activities

Darpp-32 is a substrate for and negative regulator of PKA. Although the relationship between t-Darpp and PKA has yet to be elucidated, El-Rifai’s group recently reported that exogenous expression of t-Darpp in AGS gastric carcinoma cells leads to
increased phosphorylation of CREB, a PKA substrate, and increased CRE binding activity [32]. One explanation for this observation may be that, opposite to Darpp-32, t-Darpp acts as an activator of PKA or has a dominant-negative effect on Darpp-32’s inhibitory activity. To determine the effect of t-Darpp and Darpp-32 overexpression on PKA activity, we performed an electrophoretic mobility shift assay on nuclear extracts derived from SK.tDp.A cells and three independent SK.tDp/Dp32 clones, using a consensus CRE sequence as probe. Parent SK-Br-3 cells exogenously expressing both t-Darpp and Darpp-32 (tDp/Dp32) were used as control for the respective forms of the protein; this lane was loaded with one-fifth as much lysate as the other lanes to account for their high exogenous t-Darpp/Darpp-32 expression. The top panel shows a short-exposure image of the membrane stained with an antibody (Santa Cruz H-62) that recognizes both Darpp-32 and t-Darpp. The middle panel is a long exposure of the same membrane and the bottom image shows the levels of actin as a loading control. Numbers below the actin image indicate the ratio of Darpp-32 to t-Darpp signal for each lane in the middle panel, as determined by densitometric scanning. Clones shown in this figure and additional BT/HerR clones have been analyzed multiple times by Western analysis, always with very high t-Darpp expression and low or undetectable expression of Darpp-32.

Discussion

We have previously reported on the isolation and initial characterization of BT/HerR1.0 cells that are highly resistant to Herceptin [8]. Those cells were derived by culturing the Her2-dependent, Herceptin-sensitive BT474 human breast cancer cells in the presence of 1.0 μM Herceptin for 5–6 months. Gene
profiling was subsequently performed to determine the full complement of gene expression changes in BT/HerR clones. That analysis revealed changes in a number of genes that intersect with the PKA signaling pathway as either direct or indirect regulators of PKA activity. These include down-regulation of the gene for PKA-RIIα, a PKA regulatory subunit; down-regulation of PKIγ, an endogenous inhibitor of PKA [27]; upregulation of PPP1R1B, which codes for Darpp-32 and its transcriptional variant t-Darpp [29,34]; and down-regulation of PPP1R3C, whose gene product has multiple functions including promotion of protein phosphatase-1 (PP-1) activity and modulation of Darpp-32 function [28]. The net effect of these changes is 2- to 4-fold activation of PKA signaling activity in BT/HerR cells (manuscript submitted).

In the current report, we demonstrate that it is the amino-terminal truncated protein, t-Darpp, that was predominantly overexpressed in BT/HerR cells selected for Herceptin resistance (Fig. 1) and that exogenous overexpression of t-Darpp was sufficient for conferring Herceptin resistance on Her2-positive SK-Br-3 cells (Fig. 2). These results are consistent with the recent report from Belkhiri et al. using independently derived Herceptin-resistant cell lines and transfected cells [31]. Hamel et al. also demonstrate that t-Darpp overexpression can confer resistance [35]. We go on to demonstrate that high expression of the full-length protein, Darpp-32, was able to reverse t-Darpp’s effects on Herceptin-resistant cell growth and phospho-Akt levels (Fig. 3). In fact, overexpression of Darpp-32 alone appeared to be deleterious to cell survival, since we were never able to obtain long-term cultures of SK-Br-3 cells that overexpress Darpp-32. These data suggest that Darpp-32 and t-Darpp have antagonistic effects on cell growth and/or survival.

In addition to conferring Herceptin resistance, t-Darpp is also reported to confer resistance to drug-induced apoptosis, apparently via a mechanism that involves CREB activation [32]. We also show a relationship between t-Darpp overexpression and CREB activation and this was reversed by co-expression of Darpp-32 (Fig. 4). Although not definitive, the most likely means by which CREB is influenced by t-Darpp/Darpp-32 is via the PKA signaling pathway. This would be consistent with the overall implication of PKA regulatory proteins in Herceptin resistance discussed earlier and the known function of Darpp-32 as a PKA inhibitor [29], but the mechanism by which t-Darpp might influence this pathway is not known. Because the full-length Darpp-32 is both a substrate for phosphorylation by PKA (at Thr-34) and a feedback negative regulator of PKA, it is interesting to speculate that t-Darpp might function by antagonizing Darpp-32’s

![Figure 2](image-url)
Figure 3. Full-length Darpp-32 reverses Herceptin resistance conferred by t-Darpp. (A) The tDp.A clone was transfected with an empty pcDNA3.1/Zeo vector (NZ1 and NZ2) or with the pcDNA3.1/Darpp-32 vector (tDp/Dp32.A, D, F, and K). Expression of t-Darpp and Darpp-32 in these cell lines and parent SK-Br-3 cells was analyzed by Western hybridization using the H-62 anti-Darpp-32 antibody. (B) Growth of SK-Br-3, tDp.A, and tDp/Dp32.D, F, and K was analyzed in the presence and absence of Herceptin (0.1 μM or 0.3 μM) for 7 days. Shown are the absorbances (average of triplicate wells, +S.D.) for cells incubated in the presence of Herceptin, normalized to the same cells grown in the absence of Herceptin. (C) Total and phospho-Akt levels in SK-Br-3, tDp/Dp32.D, and tDp/Dp32.F clones at the indicated times (hrs) after the addition of Herceptin, analyzed by Western hybridization. This experiment was performed three times, twice with 1.0 μM Herceptin, once with 0.2 μM Herceptin. We show the results with 0.2 μM Herceptin, representative of all three experiments showing loss of phospho-Akt signal by 4 hours.

doi:10.1371/journal.pone.0006220.g003

Figure 4. t-Darpp and Darpp-32 have antagonistic effects on CRE binding activity. Nuclear CRE binding activity in parent SK-Br-3 cells (SK) and the indicated transfected clones was analyzed by EMSA, as described in Materials and Methods. Quantification of band density, relative to the SK lane, is shown below each lane. The experiment was performed twice and the relative band densities for the other experiment were 1.9 for tDp.A and 1.1, 0.5 and 0.4 for the three tDp/Dp32 clones, respectively.

doi:10.1371/journal.pone.0006220.g004
feedback inhibition of PKA, thereby potentiating PKA signaling. The downstream effects of PKA signaling include phosphorylation and activation of full-length Darpp-32 as a PP-1 inhibitor [29]. Notably, the Thr-34 phosphorylation site and PP-1 binding domain are missing from t-Darpp, suggesting that its overexpression should not have a direct effect on PP-1 activity.

There could be multiple downstream effects of PP-1 inhibition and/or PKA activation, including the sustained phosphorylation and constitutive activation of Akt that is observed in Herceptin resistant cells. As noted earlier, Belkhiri et al. found that t-Darpp is anti-apoptotic and promotes resistance to cytotoxic agents, additional effects that could be mediated through PP-1 or more directly through PKA [31,32]. One final observation from our reported microarray data is the down-regulation of PPP1R3C in BT/HerR1.0 clones. The corresponding gene product, PTG, is a scaffolding protein that can stimulate PP-1 activity and also has been reported to interfere with Darpp-32’s inhibition of PP-1 [28]. Thus, down-regulation of PTG would be consistent with a mechanism that results in overall inhibition of PP-1 and sustained Akt phosphorylation.

Based on the findings in the current report, our previous observations on the role of PKA and its regulatory proteins in Herceptin resistance, and the work of Belkhiri et al., we propose a working model in which down-regulation of PKA-RIIα, PKIγ and PTG and up-regulation of t-Darpp work in concert to enhance PKA enzyme activity and inhibit PP-1, thereby allowing sustained activation of the PI3K/Akt pathway in the presence of Herceptin, and promoting cell growth and survival. This model is illustrated in Fig. 5. Additional direct or indirect effects of t-Darpp overexpression on Her2 or Akt or other downstream effects of PKA dysregulation, as suggested by Belkhiri et al. [31], might also contribute to the resistance phenotype. It is worth noting that this same group has not reported the anti-resistance effects of Darpp-32 overexpression that we demonstrate here. In fact, those authors claim that Darpp-32 is able to confer resistance to chemotherapy-induced apoptosis in a colon cancer cell line (RKO) and a gastric cancer cell line (AGS) [33]. Interestingly, Darpp-32 (but not t-Darpp) overexpression results in increased basal apoptosis rates in AGS cells and the protection against drug-mediated apoptosis is more pronounced with t-Darpp overexpression than with Darpp-32 overexpression in those cells. This is especially true for ceramide, a drug that activates protein phosphatases such as PP-1 and PP2A, thus indirectly inhibiting Akt signaling. Hamel et al. also suggest that Darpp-32 is able to confer resistance to Herceptin.

Figure 5. A working model of Herceptin resistance in BT/Her6 cells. Several intracellular changes, including down-regulation of PKA-RIIα, PKIγ and PTG (green arrows) and up-regulation of t-Darpp (red arrow) work coordinately to enhance PKA activity. PKA, in turn, either activates the PI3K/Akt pathway (possibly through EGFR or the p85 regulatory subunit of PI3K) or promotes sustained phospho-Akt levels by activating the PP-1 inhibitory activity of Darpp-32. This activity is stimulated via a phosphorylation event at Thr-34, which is absent from t-Darpp. A second phosphorylation event, at Thr-75, activates Darpp-32 as a PKA inhibitor. We speculate that t-Darpp may interfere with this PKA inhibition via a dominant negative mechanism. Dashed lines indicate activities that are down-regulated in BT/Her6 cells relative to BT474 cells. Question marks indicate hypothetical pathways that are activated in BT/Her6 cells. All other pathways represent well established activities associated with the indicated proteins and enzymes. Abbreviations not already cited: PDK1/2, 3-phosphoinositide-dependent kinase-1/2; Pten, phosphatase and tensin homologue deleted in chromosome 10; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate.

doi:10.1371/journal.pone.0006220.g005
[35], but there is no direct demonstration of Darpp-32 expression in cells analyzed for the Herceptin phenotype in that study. The possible conflicts or overlaps between our current observations and those of Belkhiri et al. and Hamel et al. still need to be resolved, but they could be due to different cell lines used, different levels of expression, gene expression, or other factors affecting the intracellular function of Darpp-32.

There could be a broader role for t-Darpp and/or Darpp-32 in malignancy, beyond an involvement in drug resistance. A protein(s) cross-reacting with Darpp-32 antibody and mRNA corresponding to Darpp-32 and t-Darpp are detected in a variety of adenocarcinomas, including breast cancers [30,33,34]. Using antibodies that detect either Darpp-32 alone or both Darpp-32 and t-Darpp, we have found frequent high-level expression of one or both proteins in both Her2-positive and Her2-negative breast cancers (unpublished observations). Work in the current report would suggest that it is t-Darpp, or perhaps the ratio between t-Darpp and Darpp-32, that is critical for both malignant growth and clinical outcome of these cancers, but further analysis will be required to determine if this is the case. If it is, then t-Darpp (or, more generally, the PKA pathway) could become a new target for therapy and/or a biomarker for response to drug therapy. Moreover, it will be interesting to study the mechanism by which cells regulate expression from the upstream (Darpp-32) and downstream (t-Darpp) transcriptional start sites in the PPP1R1B gene, since shifting the balance towards the t-Darpp start site could have profound effects on both malignancy and drug resistance.

Acknowledgments

The authors gratefully acknowledge Wael El-Rifai (Vanderbilt University Medical Center) for supplying the Darpp-32 and t-Darpp cDNAs.

References

1. Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26: 55–59.
2. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147–1157.
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2649.
4. Esteve FJ, Valero V, Booser D, Guerra LT, Murray JL, et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–1808.
5. Seidman AD, Forster MN, Esteve FJ, Tan L, Kaptain S, et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2387–2395.
6. Simons DJ, Leyland-Jones B, Shab S, H. F., Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.
7. Vogel CL, Cobleigh MA, Tripathy D, Gutheil TG, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726.
8. Chan CT, Metz MZ, Kane SE (2005) Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3-kinase (PI-3K) and erythropoietin receptor (EGRF) kinase inhibitors. Breast Cancer Res Treat 91: 187–201.
9. Nahta R, Esteve FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123–130.
10. Nokes FM, Cintratulabaw W, Riter CA, King W, Seelig S, et al. (2002) Herceptin-induced inhibition of phosphatidylinositol-3-kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Research 62: 4132–4141.
11. Yuan TL, Canly LE (2008) PIK pathway alterations and cancer: variations on a theme. Oncogene 27: 5497–5510.
12. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of PTEN gene inactivation in breast cancer. Cancer Res 64: 3981–3986.
13. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major mechanism of acquired resistance to trastuzumab in ErbB2-overexpressing metastatic breast cancer. J Clin Oncol 25: 395–402.
14. Nagy A, Lan KH, Zhou X, Tan M, Esteve FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 12: 395–402.
15. Fujita T, Doihara H, Kawasaki K, Takahata D, Takahashi H, et al. (2006) PI3K activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94: 247–252.
16. Lu Y, Zi X, Zhao Y, Mascarénhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852–1857.
17. Shattuck DL, Miller JK, Carrasquillo KL, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research 68: 1471–1477.
18. Miller KD (2004) The role of ErbB inhibitors in trastuzumab resistance. The Oncologist 9(suppl3): 16–19.
19. Ritter CA, Perez-Torres M, Reichert C, Guix M, Dugger T, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909–4919.
20. Stern DF (2008) ErbB3/Her3 and ErbB2/Her2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 13: 213–223.
21. Brougrod, Newman AC (2008) PHLPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab 19: 223–230.
22. Xu W, Yuan X, Jung T, Yang Y, Banu A, et al. (2003) The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PI3-kinase-dependent inactivation of Akt in ErbB2 overexpressing breast cancer cells. Cancer Research 63: 7777–7784.
23. Coulembier H, Bollen M (2003) Functional diversity of protein phosphatase-1, a cellular enzyme and a drug target. Biochem J 364: 1–9.
24. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteve FJ (2004) P27Kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Research 64: 3981–3986.
25. Le X-F, Arachchige-Dun AS, Mao W, Horne MC, Bast RC (2007) Roles of the protein kinase inhibitor of cAMP-dependent protein kinase. J Biol Chem 282: 20198–20204.
26. Brady MJ, Printen JA, Mastick CC, Saltiel AR (1997) Role of protein targeting to ER in the regulation of p27kil and cyclin D1 protein levels. J Biol Chem 272: 1852–1857.
27. Collins SP, Uhrer M (1997) Characterization of PKGgamma, a novel isoform of the protein kinase inhibitor of cAMP-dependent protein kinase. J Biol Chem 272: 20189–20194.
28. Brady MJ, Printon JA, Mastick CC, Saltiel AR (1997) Role of protein targeting to ER in the regulation of p27kil and cyclin D1 protein levels. J Biol Chem 272: 20189–20194.
29. Savranovsoff P, Nishi A, Fisone G, Giraudot J, Nairn AC, et al. (2004) DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44: 269–280.
30. Beckler A, Moskalik CA, Zaika A, Hampton GM, Powell SM, et al. (2003) Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3′,5′-monophosphate-regulated phosphoprotein in common adenocarcinomas. Cancer 98: 1547–1551.
31. Belkhiri A, Dar AA, Peng DF, Raevi MH, Rinehart C, et al. (2006) Expression of the t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res 14: 4564–4571.
32. Belkhiri A, Dar AA, Zaika A, Kelley M, El-Rifai W (2008) t-Darpp promotes cancer cell survival by up-regulation of bcl2 through Akt-dependent mechanism. Cancer Research 68: 395–403.
33. Belkhiri A, Zaika A, Pidkovka N, Knuutila S, Moskalik C, et al. (2005) Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res 65: 6583–6592.
34. El-Rifai W, Smith MJF, Li GM, Beckler A, Carl VS, et al. (2002) Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Research 62: 4091–4094.
35. Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, et al. (2009) Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers. Breast Cancer Res Treat.